MedTrace Logo

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

NCT00441818 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2008-05-09

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.

Conditions

  • Hodgkin's Lymphoma

Interventions

DRUG

TNX-650

Sponsors & Collaborators

  • Tanox

    lead INDUSTRY

Principal Investigators

  • Anas Younes, MD · M.D. Anderson Cancer Center

  • Craig Moskowitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441818 on ClinicalTrials.gov